BIOCRYST PHARMACEUTICALS, INC.
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1986-01-01
- Employees
- 536
- Market Cap
- $1.7B
- Website
- http://www.biocryst.com
First-in-Human Study of BCX9930 in Healthy Volunteers and Patients With PNH
- Conditions
- Interventions
- First Posted Date
- 2020-04-01
- Last Posted Date
- 2022-02-17
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 168
- Registration Number
- NCT04330534
- Locations
- 🇬🇧
Study Site, London, United Kingdom
A Study to Evaluate the Safety, Pharmacokinetics and Antiviral Effects of Galidesivir in Yellow Fever or COVID-19
- First Posted Date
- 2019-03-27
- Last Posted Date
- 2021-05-27
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03891420
- Locations
- 🇧🇷
Hospital de Clinicas da Universidade Federal do Parana, Curitiba, Parana, Brazil
🇧🇷Foundation Regional Faculty of Medicine of São José do Rio Preto, São José Do Rio Preto, SP, Brazil
🇧🇷Clinical Research Unit and Department of Infectious and Parasitic Diseases Hospital das Clínicas, School of Medicine, USP, São Paulo, SP, Brazil
Study to Evaluate the Efficacy and Safety of BCX7353 as an Oral Treatment for the Prevention of HAE Attacks in Japan
- Conditions
- Interventions
- First Posted Date
- 2019-03-13
- Last Posted Date
- 2024-07-19
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 19
- Registration Number
- NCT03873116
- Locations
- 🇯🇵
Study Site, Tokyo, Japan
🇯🇵Study Center, Saga, Japan
A Study to Evaluate the Single Dose Safety, Tolerability and Pharmacokinetics of IV BCX4430
- First Posted Date
- 2019-01-11
- Last Posted Date
- 2021-07-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 32
- Registration Number
- NCT03800173
- Locations
- 🇺🇸
PRA Health Sciences, Lenexa, Kansas, United States
Efficacy and Safety Study of BCX7353 as an Oral Treatment for the Prevention of Attacks in HAE
- Conditions
- Interventions
- First Posted Date
- 2018-04-03
- Last Posted Date
- 2023-06-26
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 121
- Registration Number
- NCT03485911
- Locations
- 🇺🇸
Study Site, Charlotte, North Carolina, United States
🇬🇧Study Center, Plymouth, United Kingdom
🇺🇸Study center, Dallas, Texas, United States
A Long Term Safety Study of BCX7353 in Hereditary Angioedema
- First Posted Date
- 2018-03-21
- Last Posted Date
- 2023-06-18
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 387
- Registration Number
- NCT03472040
- Locations
- 🇬🇧
Study center, Birmingham, United Kingdom
🇬🇧Study Center, Southampton, United Kingdom
Study of BCX7353 as a Treatment for Attacks of Hereditary Angioedema
- First Posted Date
- 2017-08-04
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 58
- Registration Number
- NCT03240133
- Locations
- 🇮🇹
Study center, Padova, Italy
🇬🇧Study Center, Southampton, United Kingdom
A Relative Bioavailability Study of Two Formulations of BCX7353
- First Posted Date
- 2017-06-29
- Last Posted Date
- 2020-01-27
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 24
- Registration Number
- NCT03202784
- Locations
- 🇬🇧
Quotient Clinical, Nottingham, United Kingdom
A Drug-Drug Interaction Study to Evaluate Drug Transporter Interactions
- Conditions
- Interventions
- First Posted Date
- 2017-05-02
- Last Posted Date
- 2017-10-26
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 54
- Registration Number
- NCT03136237
- Locations
- 🇬🇧
Covance CRU, Leeds, United Kingdom
Efficacy and Safety of BCX7353 to Prevent Angioedema Attacks in Subjects With Hereditary Angioedema
- First Posted Date
- 2016-08-18
- Last Posted Date
- 2021-03-23
- Lead Sponsor
- BioCryst Pharmaceuticals
- Target Recruit Count
- 75
- Registration Number
- NCT02870972